Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer.
Medical School Affiliated With HCA Healthcare Welcomes Its First Class
A new medical school established in partnership with U.S. healthcare giant HCA Healthcare has welcomed its first class. The 50 students of the inaugural class